A new therapeutic opportunity in Crimean-Congo hemorrhagic fever: Targeting the stalk domain of viral nucleocapsid protein for therapeutic intervention

Crimean-Congo hemorrhagic fever virus (CCHFV) is a high-consequence pathogen for which no approved antivirals or vaccines exist. The viral nucleocapsid protein (N protein) is central to the Nairovirus life cycle, coordinating genomic RNA encapsidation and selective enhancement of viral mRNA translation through its interaction with the panhandle-like hairpin structure in the S-segment mRNA 5' untranslated region (UTR). Here, we developed a robust fluorescence polarization anisotropy (FPA) based high-throughput assay capable of quantitatively monitoring the interaction between purified N protein and the viral 5'UTR hairpin. The assay demonstrated excellent stability, DMSO tolerance, and performance metrics (average Z' > 0.6), enabling the screening of 108,947 small molecules. Primary screening identified 122 inhibitors, 86 of which showed clear dose-responsive activity. Cluster analysis, medicinal chemistry filtering, and repurchase-based validation yielded 37 confirmed hits, from which compounds 11, 14, and 33 were prioritized for further testing. Biochemical analysis demonstrated that all three compounds noncompetitively inhibit N protein-UTR binding with IC₅₀ values of 11-41 μM. These compounds exhibited minimal cytotoxicity (CC₅₀ > 1-2 mM) and potent antiviral activity in cell culture against Hazara virus (HZV), a BSL-2 surrogate for CCHFV, with EC₅₀ values of ~23-51 μM and favorable selectivity indices (>34-86). Plaque assays further showed that compounds 11 and 14 reduced the production of infectious viral particles by over 100-fold, whereas compound 33 nearly eliminated detectable infectious virus in the media. Mechanistic assays revealed that these inhibitors act during post-entry steps and selectively block the N protein-mediated enhancement of viral mRNA translation without affecting the canonical host translation machinery. Molecular modeling and biochemical/translation assays support binding of compound 11 to the N protein stalk-head interface, involving residues Gln300, Glu240 and Lys473. Collectively, these findings identify the N protein-5'UTR interface as a tractable antiviral target and establish first-in-class small-molecule inhibitors that disrupt essential Nairovirus RNA-N protein interaction. These compounds provide strong leads for further optimization and development of urgently needed therapeutics for CCHFV.

Authors

Institutions

Publication Details

Journal
PLoS Pathogens
Published
2026-11-20
DOI
https://doi.org/10.1371/journal.ppat.1014772
Primary Topic
Viral Infections and Vectors
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A new therapeutic opportunity in Crimean-Congo hemorrhagic fever: Targeting the stalk domain of viral nucleocapsid protein for therapeutic intervention

Mohammad Ayoub Mir, Hoangvi Le, Anuradha Roy, Austin Royster et al.
2 links
PLoS Pathogens
Viral Infections and Vectors
article

A new therapeutic opportunity in Crimean-Congo hemorrhagic fever: Targeting the stalk domain of viral nucleocapsid protein for therapeutic intervention

Mohammad Ayoub Mir, Hoangvi Le, Anuradha Roy, Austin Royster, Sheema Mir, Saima Ali, Xin Li, Yongcheng Song, Songyang Ren, Ethan Mir
article en

Abstract

Crimean-Congo hemorrhagic fever virus (CCHFV) is a high-consequence pathogen for which no approved antivirals or vaccines exist. The viral nucleocapsid protein (N protein) is central to the Nairovirus life cycle, coordinating genomic RNA encapsidation and selective enhancement of viral mRNA translation through its interaction with the panhandle-like hairpin structure in the S-segment mRNA 5' untranslated region (UTR). Here, we developed a robust fluorescence polarization anisotropy (FPA) based high-throughput assay capable of quantitatively monitoring the interaction between purified N protein and the viral 5'UTR hairpin. The assay demonstrated excellent stability, DMSO tolerance, and performance metrics (average Z' > 0.6), enabling the screening of 108,947 small molecules. Primary screening identified 122 inhibitors, 86 of which showed clear dose-responsive activity. Cluster analysis, medicinal chemistry filtering, and repurchase-based validation yielded 37 confirmed hits, from which compounds 11, 14, and 33 were prioritized for further testing. Biochemical analysis demonstrated that all three compounds noncompetitively inhibit N protein-UTR binding with IC₅₀ values of 11-41 μM. These compounds exhibited minimal cytotoxicity (CC₅₀ > 1-2 mM) and potent antiviral activity in cell culture against Hazara virus (HZV), a BSL-2 surrogate for CCHFV, with EC₅₀ values of ~23-51 μM and favorable selectivity indices (>34-86). Plaque assays further showed that compounds 11 and 14 reduced the production of infectious viral particles by over 100-fold, whereas compound 33 nearly eliminated detectable infectious virus in the media. Mechanistic assays revealed that these inhibitors act during post-entry steps and selectively block the N protein-mediated enhancement of viral mRNA translation without affecting the canonical host translation machinery. Molecular modeling and biochemical/translation assays support binding of compound 11 to the N protein stalk-head interface, involving residues Gln300, Glu240 and Lys473. Collectively, these findings identify the N protein-5'UTR interface as a tractable antiviral target and establish first-in-class small-molecule inhibitors that disrupt essential Nairovirus RNA-N protein interaction. These compounds provide strong leads for further optimization and development of urgently needed therapeutics for CCHFV.

PLoS PathogensVol. 22(11)
University of Kansas (US), University of California, Los Angeles (US), Baylor College of Medicine (US), Western University of Health Sciences (US)
U.S. Department of Defense, National Institutes of Health, National Institute of General Medical Sciences
Good health and well-being
Viral Infections and Vectors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon